AIM Company Profile and Key Details

Q: Who are the executives of AIM?

Dr. Carol A. SmithChief Manufacturing Officer & Deputy Chief Scientific OfficerDr. Christopher McAleer Ph.D.Scientific OfficerDr. David R. Strayer M.D.Chief Scientific Officer & Medical DirectorAnn Marie E. CoverlyDirector of Admin. & HR and Deputy Investor Relations CoordinatorJodie PelzControllerDr. Ralph Christopher Cavalli Ph.D.Vice President of QC & ManufacturingMr. Thomas K. Equels Esq., J.D., M.S.Executive Vice Chairman, Chief Executive Officer & PresMr. Peter W. Rodino III, Esq., J.D.Chief Operating Officer, Executive Director of Gov.al Relations, Gen. Counsel & Sec.

AMEX : AIM

AIM ImmunoTech

$0.22

-0.0052-2.29%

At Close 4:00 PM

$0.22

−0.0108-4.76%

Pre-Market 08:30 PM

63.57

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

AIM ImmunoTech Inc. (AIM) stock declined over -2.29%, trading at $0.22 on AMEX, down from the previous close of $0.23. The stock opened at $0.22, fluctuating between $0.22 and $0.22 in the recent session.

Stock Snapshot

0.2269

Prev. Close

754.57K

Market Cap

0.2152

Day Low

-0.03

P/E Ratio

-6.37843

EPS (TTM)

-0.45

Cash Flow per Share

0.22

Open

3.4M

Number of Shares

0.2241

Day High

95.49%

Free Float in %

0.21

Book Value

3.24M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Sep 11, 2026	0.22	0.22	0.22	0.22	3.29M
Sep 10, 2026	0.22	0.23	0.22	0.23	10.38M
Sep 09, 2026	0.23	0.24	0.23	0.23	8.83M
Sep 08, 2026	0.23	0.24	0.23	0.23	5.84M
Sep 04, 2026	0.23	0.24	0.23	0.23	8.52M
Sep 03, 2026	0.25	0.26	0.23	0.23	0
Sep 02, 2026	0.23	0.25	0.23	0.23	8.62M
Sep 01, 2026	0.24	0.25	0.23	0.24	38.16M
Aug 31, 2026	0.37	0.37	0.20	0.23	125.45M
Aug 28, 2026	0.26	0.26	0.25	0.26	325.46K
Aug 27, 2026	0.25	0.26	0.25	0.25	448.81K
Aug 26, 2026	0.25	0.26	0.25	0.25	377.56K
Aug 25, 2026	0.25	0.26	0.25	0.25	648.02K
Aug 24, 2026	0.26	0.26	0.25	0.25	423.12K
Aug 21, 2026	0.26	0.27	0.25	0.26	871.4K
Aug 20, 2026	0.24	0.26	0.24	0.25	583.26K
Aug 19, 2026	0.24	0.26	0.24	0.24	1.14M
Aug 18, 2026	0.24	0.26	0.23	0.23	0
Aug 17, 2026	0.23	0.26	0.23	0.24	2.1M
Aug 14, 2026	0.25	0.26	0.19	0.22	1.82M

Contact Details

Ocala, FL 34473

United States

https://aimimmuno.com 352 448 7797

About Company

AIM ImmunoTech Inc., an immuno-pharmaceutical company based in Ocala, Florida, focuses on discovering and advancing treatments for a diverse array of cancers, viral infections, and immune system disorders across the United States. Its primary drug offerings include Ampligen (rintatolimod), a large macromolecular double-stranded ribonucleic acid compound developed for chronic fatigue syndrome, and Alferon N Injection (Interferon alfa), a purified, naturally derived, multi-species alpha interferon prescribed for genital warts. Furthermore, Ampligen is currently undergoing investigation for its potential application in treating pancreatic, renal cell, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company, originally incorporated in 1966, was formerly known as Hemispherx Biopharma, Inc. until its name change in August 2019.

Stock Peers

PTHS

-0.53-2.36%

Pelthos Therapeutics Inc.$21.90 AGE

-1.5-11.90%

AgeX Therapeutics, Inc.$11.10 CYBN

0.1+1.22%

Cybin Inc.$8.28 NRXS

0.05+0.88%

NeurAxis, Inc.$5.74 ARMP

0.15+2.87%

Armata Pharmaceuticals, Inc.$5.38 PLX

-0.09-3.30%

Protalix BioTherapeutics, Inc.$2.64 CANF

0.17+7.87%

Can-Fite BioPharma Ltd.$2.33 SER

-0.28-11.20%

Serina Therapeutics, Inc.$2.22 APUS

-0.065-3.00%

Apimeds Pharmaceuticals US, Inc$2.11 KAPA

0.07+4.17%

Kairos Pharma, Ltd.$1.75

Company Overview

AIM ImmunoTech Inc. (AMEX:AIM) closed at $0.22 USD, losing -$0.01 (-2.29%) from the previous close of $0.23. The stock is currently mid-range between its 52-week high and low $0.19 and $2.89. With a market capitalization of about $754.57 thousand, AIM ImmunoTech Inc. is classified as a micro-cap and shows market-like volatility (beta ~1.19). Key stats such as the average daily volume over the past year has been around 5.28 million shares, volume is running light vs its 52-week average. Headquartered in Ocala, FL, AIM ImmunoTech Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Thomas K. Equels, the company employs approximately 19 people and listed since November 02, 1995. AIM ImmunoTech Inc., an immuno-pharmaceutical company based in Ocala, Florida, focuses on discovering and advancing treatments for a diverse array of cancers, viral infections, and immune system disorders across the United States.

Technical Performance

Short-term trend indicators are bullishly aligned (SMA20 -8.27%, SMA50 -17.44%, SMA200 -73.02%). The stock’s 14-day RSI is 43.33 (neutral), while the ATR of 0.16 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -97.25% below its high and over 29.36% above its low. Average 10-day trading volume of 6.50 million shares is slightly above the 3-month average of 4.83 million, indicating heightened recent market interest.

Valuation Metrics

AIM ImmunoTech Inc. trades at a P/E ratio of -0.06, slightly below the S&P 500 average, with a price-to-sales ratio of 7.95 and a price-to-book ratio of 0.49 suggesting the stock is closer to book value. The P/FCF stands at -0.11, also above market averages.

Dividend & Fair Value

AIM ImmunoTech Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.29. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

AIM ImmunoTech Inc. generated EPS of -$20.14 over the past year. Five-year average earnings growth is 34.59%. The latest quarter delivered EPS of -$0.43. The next quarter is forecast at -$0.94. Next year's EPS is expected at $2.17. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 4 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $24.00 to $9.00. The high target offers 10809.09% upside. The low target suggests 3990.91% downside. The mean target is $16.75. This offers 7513.64% upside. AIM ImmunoTech Inc. earnings surprise history is a mixed track record. The quarter that ended August 07, 2026, missed forecasts by 152.94%. The prior quarter beat by 86.49%. Over the last six quarters, Apple has recorded several small beats. These include -37.5% in May 15, 2025.

Shareholding & Insider Activity

AIM ImmunoTech Inc. has 35.51 million shares outstanding. The public float is 27.69 million shares, elevated short interest at 1.89% of float. This equals 572.58 thousand shares. The short ratio is 0.08 days. Institutional investors hold 0.76% of the float. Insiders own 0.59%. KELLNER TED D holds 1.97 million shares, CARTER WILLIAM A has 1.23 million shares and MITCHELL WILLIAM M has 521.72 thousand shares.

Financial & Profitability Overview

Over the trailing twelve months, AIM ImmunoTech generated $202.00K in revenue, or $0.00 per share. Gross margin was -38.61%, operating margin -15793.07%, and net profit margin -14337.62%. Returns are negative, with ROA at -149.15% and ROE at -283.00%.
On valuation metrics, AIM ImmunoTech trades at a P/E of -0.06, P/S of 7.95 and P/B of 0.49. The current ratio is 2.11 and quick ratio is 2.11. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -818.69 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.51, supported by a cash flow-to-debt ratio of -1.80.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, AIM ImmunoTech posted revenue of $202.00K, down slightly from $141.00K in the prior quarter. Gross profit was - $78.00K (margin -38.61%). Operating income was - $31.90M (margin -15793.1%). Net income was- $28.96M (EPS - $0.60).
The company ended the quarter with $13.07M in cash and short-term investments, a total debt of $718.00K, and net debt of - $4.72M. Total assets were $19.42M, with equity of $10.23M. Financials further reflected weakness, with operating cash flow of - $21.27M, free cash flow of - $21.85M, and capital expenditures of - $585.00K.

Price Forecast & Outlook

Our AI price prediction model suggests that AIM ImmunoTech Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -0.77%, with price expected at $0.22 by September 25, 2026, within a range of $0.20 to $0.23 3-Month Outlook: Projected fall of -100.0%, reaching $0.00 by December 10, 2026, with a range of $0.00 to $0.15. 1-Year Outlook: Projected loss of -90.98%, with price at $0.02 by September 10, 2027, within a range of $0.00 to $0.00.

Key Takeaways

AIM ImmunoTech Inc. (AMEX:AIM) shares are flat 4.53% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows AIM ImmunoTech Inc. trading at a premium to the broader market with a P/E of -0.06. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $11.07, suggesting 4893.23% upside. Our AI forecast model points to short-term weakness (-0.77% over two weeks), a medium-term fall (-100.0% over three months), and a longer-term loss (-90.98% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current AIM ImmunoTech Inc. (AIM) stock price?

AIM ImmunoTech Inc. (AMEX: AIM) stock price is $0.22 in the last trading session. During the trading session, AIM stock reached the peak price of $0.22 while $0.22 was the lowest point it dropped to. The percentage change in AIM stock occurred in the recent session was -2.29% while the dollar amount for the price change in AIM stock was - $0.01.

AIM's industry and sector of operation?

The AMEX listed AIM is part of Biotechnology industry that operates in the broader Healthcare sector. AIM ImmunoTech Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of AIM?

Dr. Carol A. Smith
Chief Manufacturing Officer & Deputy Chief Scientific Officer
Dr. Christopher McAleer Ph.D.
Scientific Officer
Dr. David R. Strayer M.D.
Chief Scientific Officer & Medical Director
Ann Marie E. Coverly
Director of Admin. & HR and Deputy Investor Relations Coordinator
Jodie Pelz
Controller
Dr. Ralph Christopher Cavalli Ph.D.
Vice President of QC & Manufacturing
Mr. Thomas K. Equels Esq., J.D., M.S.
Executive Vice Chairman, Chief Executive Officer & Pres
Mr. Peter W. Rodino III, Esq., J.D.
Chief Operating Officer, Executive Director of Gov.al Relations, Gen. Counsel & Sec.

How AIM did perform over past 52-week?

AIM's closing price is 16.68% higher than its 52-week low of $0.19 where as its distance from 52-week high of $2.89 is -92.33%.

How many employees does AIM have?

Number of AIM employees currently stands at 19.

Link for AIM official website?

Official Website of AIM is: https://aimimmuno.com

How do I contact AIM?

AIM could be contacted at phone 352 448 7797 and can also be accessed through its website. AIM operates from 2117 SW Highway 484, Ocala, FL 34473, United States.

How many shares of AIM are traded daily?

AIM stock volume for the day was 3.24M shares. The average number of AIM shares traded daily for last 3 months was 5.28M.

What is the market cap of AIM currently?

The market value of AIM currently stands at $754.57K with its latest stock price at $0.22 and 3.4M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	19
Beta	1.19
Sales or Revenue	$202.00K
5Y Sales Change%	-0.989%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

AIM Company Profile and Key Details

AIM ImmunoTech

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Company Overview

Earnings & Analyst Outlook

Dividend & Fair Value

Valuation Metrics

Price Forecast & Outlook

Key Takeaways